Rapid Diagnosis of Influenza Virus Infection in Different Age Groups

2012 ◽  
Vol 21 (4) ◽  
pp. 115-126
Author(s):  
Maha Kamal Gohar
2017 ◽  
Vol 16 (5) ◽  
pp. 80-86
Author(s):  
E. I. Burtseva ◽  
E. A. Mukasheva ◽  
A. G. Rosatkevich

This paper presents the risk analysis of influenza virus infection in different age groups based on the prevalence and mortality rates. The epidemiological characteristics of the influenza virus circulation during postpandemic period are given. Main aspects of specific and non-specific influenza prevention are discussed. The efficacy of the interferon-based medication Grippferon in the prevention of influenza and acute respiratory viral infections (ARVI) is justified.


Author(s):  
Melissa Rioux ◽  
Mara McNeil ◽  
Magen Francis ◽  
Nicholas Dawe ◽  
Mary Foley ◽  
...  

Influenza virus infection causes severe respiratory illness in people worldwide, disproportionately affecting infants. The immature respiratory tract coupled with the developing immune system is thought to synergistically play a role in the increased disease severity in younger age groups. Although vaccines remain the best solution for protecting this vulnerable population, no vaccines are available for those under 6 months, and for infants aged 6 months to 2 years, the vaccine elicits a dampened immune response. Dampened immune responses may be due to unique features of the infant immune system and a lack of pre-existing immunity. Unlike older children and adults, the infant immune system is Th2 skewed and has less antigen presenting cells and soluble immune factors. Paradoxically, we know that a person’s first infection with the influenza virus during infancy or childhood leads to the establishment of life-long immunity toward that particular virus strain. This is called influenza imprinting. To provide better protection against influenza virus infection and disease in infants, more research must be conducted to understand the imprinting event. We contend that by understanding influenza imprinting in the context of the infant immune system and the infant’s immature respiratory tract, we will be able to design more effective influenza vaccines for both infants and adults. Working through the lens of imprinting, using infant influenza animal models such as mice and ferrets, which have proven useful for infant immunity studies, we will gain a better understanding of imprinting and its implications regarding vaccine design. This review examines literature regarding infant immune development, current vaccine strategies, respiratory development, and the importance of researching the imprinting event in infant animal models to develop more effective and protective vaccines for young children.


2011 ◽  
Vol 8 (1) ◽  
pp. 537 ◽  
Author(s):  
Nobuhiro Takemae ◽  
Sujira Parchariyanon ◽  
Ruttapong Ruttanapumma ◽  
Yasuaki Hiromoto ◽  
Tsuyoshi Hayashi ◽  
...  

2007 ◽  
Vol 51 (9) ◽  
pp. 903-907 ◽  
Author(s):  
Yoshimi Tsuda ◽  
Yoshihiro Sakoda ◽  
Saori Sakabe ◽  
Tsuyoshi Mochizuki ◽  
Yasuharu Namba ◽  
...  

2018 ◽  
Vol 23 (43) ◽  
Author(s):  
Pere Godoy ◽  
Arantxa Romero ◽  
Núria Soldevila ◽  
Nuria Torner ◽  
Mireia Jané ◽  
...  

Introduction When influenza vaccination is ineffective in preventing influenza virus infection, it may still reduce the severity of influenza-associated disease. Here, we estimate the effect of influenza vaccination in preventing severe outcomes e.g. intensive care unit (ICU) admission and death, even though it did not prevent influenza virus infection and subsequent hospitalisation. Methods An observational case–case epidemiological study was carried out in 12 sentinel hospitals in Catalonia (Spain) over six influenza seasons 2010/11–2015/16. Cases were individuals with severe laboratory-confirmed influenza virus infection and aged 18 years and older. For each reported case we collected demographic, virological and clinical characteristics. Logistic regression was used to estimate the crude, adjusted odd ratios (aOR) and 95% confidence intervals (CI). Results Of 1,727 hospitalised patients included in the study, 799 were female (46.7%), 591 (34.2%) were admitted to the ICU and 223 (12.9%) died. Influenza vaccination uptake was lower in cases that required ICU admission or died (21.2% vs 29.7%, p < 0.001). The adjusted influenza vaccination effectiveness in preventing ICU admission or death was 23% (95% CI: 1 to 40). In an analysis restricted to sex, age group and antiviral treatment, influenza vaccination had a positive effect on disease severity in all age groups and categories. Conclusions We found that influenza vaccination reduced the severity of disease even in cases where it did not prevent infection and influenza-associated hospitalisation. Therefore, increased vaccination uptake may reduce complications, ICU admission and death.


2021 ◽  
Author(s):  
Nischit Baral ◽  
Niranjan Nayak

Influenza is a major cause of hospitalization in all age groups but can cause more severe infections in specific high-risk population. Novel Corona Virus Disease 2019 (COVID-19) pandemic and Influenza virus infection cause similar illness and coexist. Cardiovascular complications due to influenza are important causes of morbidity and mortality in the US, especially in the elderly population (aged more than 65 years). Acute Myocardial Infarction (AMI) is the most serious among the cardiovascular causes of mortality following the attack of influenza, mainly in patients with various co-morbidities like pre-existing coronary artery disease (CAD), diabetes mellitus (DM), hypertension (HTN), and heart failure (HF). We have reviewed the association between influenza virus infection and AMI and extrapolated the beneficial effects of influenza vaccine in preventing AMI and its grave consequences. We have also highlighted about the importance of flu shot during the COVID-19 pandemic.


Sign in / Sign up

Export Citation Format

Share Document